Collaborative Model for Acceleration of Individualized Therapy of Colon Cancer
Annual rept. 15 Sep 2013-14 Sep 2014
COLORADO UNIV AURORA CO
Pagination or Media Count:
Colorectal cancer CRC represents a major health burden, and is the third leading cause of cancer deaths in the U.S. In the past decade, the median survival among patients with metastatic CRC has significantly improved, primarily due the development of active chemotherapeutic regimens that include biological agents. However, despite this success, patients soon run out of therapeutic options and receive salvage therapy that results in only a few weeks of disease stability. We have proposed to employ a team science, systems biology based approach to rapidly identify novel anti-cancer agents and individualize therapeutic strategies in preclinical CRC models. In this Year 3 Progress report, we will present the tasks and key accomplishments achieved within this period of time. In brief, we have completed all the tasks in Aim 1, and task 2 in Aim 2 in Year 3. We will continue to work on task 1 in Aim 2 for the NCE in Year 4.
- Medicine and Medical Research